Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

709
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
709
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

580
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026
Same author

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis.

Liver cancer·2026
Same author

Treatment patterns of eosinophilic esophagitis in the biologic era-a real-world analysis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

Do We Still Need a BCLC-Intermediate Stage for Hepatocellular Carcinoma-Management?

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease : Austrian Society of Gastroenterology and Hepatology (ÖGGH), Austrian Society of Diabetology (ÖDG), Austrian Society of Obesity (ÖAG).

Wiener klinische Wochenschrift·2025

Related Experiment Video

Updated: Apr 17, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.4K

Transarterial chemoembolization: modalities, indication, and patient selection.

Wolfgang Sieghart1, Florian Hucke1, Markus Peck-Radosavljevic1

  • 1Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Liver Cancer (HCC)-Study Group, Medical University Vienna, Austria.

Journal of Hepatology
|February 15, 2015
PubMed
Summary

Transarterial chemoembolization (TACE) improves intermediate-stage liver cancer care. Advances like drug-eluting bead TACE (DEB-TACE) and better response evaluation enhance outcomes and patient selection for TACE treatment.

Keywords:
HCCHepatocellular carcinomaIntermediate stageOverall survivalPatient selectionResponseTACEmRECIST

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.9K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K

Related Experiment Videos

Last Updated: Apr 17, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.4K
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.9K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K

Area of Science:

  • Hepatobiliary Medicine
  • Interventional Radiology
  • Oncology

Background:

  • Transarterial chemoembolization (TACE) is a primary treatment for intermediate-stage hepatocellular carcinoma (HCC) within the Barcelona Clinic Liver Cancer (BCLC) B stage.
  • Recent research has focused on refining TACE techniques and patient selection to optimize treatment efficacy and minimize toxicity.
  • The evolution of TACE includes the development of drug-eluting bead TACE (DEB-TACE) for improved standardization and reduced side effects.

Purpose of the Study:

  • To review advancements in TACE for intermediate-stage HCC.
  • To highlight the impact of DEB-TACE on technical standardization and toxicity reduction.
  • To discuss the role of radiologic response evaluation criteria in assessing prognostic significance and guiding treatment decisions.

Main Methods:

  • Review of recent clinical research and advancements in TACE for HCC.
  • Analysis of the introduction and benefits of DEB-TACE.
  • Examination of radiologic response evaluation criteria (EASL, mRECIST).
  • Discussion of emerging strategies for patient selection in TACE therapy.

Main Results:

  • DEB-TACE offers enhanced technical standardization and reduced TACE-related toxicity compared to conventional TACE.
  • Dynamic radiologic response evaluation criteria (EASL, mRECIST) have demonstrated prognostic significance, correlating objective tumor response with patient outcomes.
  • New approaches to patient selection are emerging, aiming to refine the use of TACE and improve outcomes for specific patient groups.

Conclusions:

  • Advancements in TACE, including DEB-TACE and refined response assessment, are improving the management of intermediate-stage HCC.
  • Objective tumor response, as assessed by criteria like mRECIST, is a crucial prognostic factor.
  • Optimized patient selection for TACE is essential to maximize benefits and mitigate risks, potentially leading to improved survival and reduced harm for patients with HCC.